Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.
The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.
Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.
Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.
In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.
- Location: Boulder, Colorado
- Core Focus: Novel therapies for rare muscle disorders
- Key Projects: Orally bioavailable small molecule therapies
- Partnerships: Supported by OrbiMed and other strategic investors
Edgewise Therapeutics (EWTX) has initiated the LYNX Phase 2 clinical trial for EDG-5506 in children with Duchenne muscular dystrophy (DMD) at Rare Disease Research in Atlanta, Georgia. The trial aims to evaluate safety, pharmacokinetics, and biomarkers of muscle damage over 12 weeks, followed by a 9-month open-label phase. Approximately 27 children aged 4 to 9 will be enrolled. EDG-5506, a novel myosin modulator, shows promise based on previous studies. Edgewise will host webinars in November to discuss the trial with the community.
Edgewise Therapeutics (NASDAQ: EWTX) announced positive interim results from its ongoing ARCH study, focusing on the safety and efficacy of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). Key findings include a significant 39% reduction in serum creatine kinase and a 75% drop in fast skeletal muscle troponin I, indicating reduced muscle damage. Improved North Star Ambulatory Assessment (NSAA) scores were also reported, with eight out of twelve participants showing functional improvement. EDG-5506 continues to be well-tolerated at increased doses, supporting its potential to alter BMD disease progression.
Edgewise Therapeutics (EWTX) will host a symposium at the 27th International Hybrid Annual Congress of the World Muscle Society in Halifax, Nova Scotia, from October 11-15, 2022. The event will feature the presentation of 6-month interim results from the ARCH study on EDG-5506, an investigational therapy for Becker Muscular Dystrophy. This therapy targets fast skeletal muscle fibers to reduce damage. Key opinion leaders will discuss related topics. The symposium is accessible only to registered attendees and will also be streamed online.
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) has successfully closed an upsized public offering of 13,372,093 shares at a price of $10.32 per share, yielding total gross proceeds of $138 million. This offering was led by J.P. Morgan and SVB Securities as joint book-running managers. The registration statement for the offering was declared effective by the
Edgewise Therapeutics (NASDAQ: EWTX) announced the pricing of an upsized public offering of 11,627,907 shares at $10.32 per share, expected to raise approximately $120 million before expenses. The offering includes an option for underwriters to purchase an additional 1,744,186 shares. The offering will close around September 16, 2022, subject to customary conditions. J.P. Morgan and SVB Securities are the joint book-running managers, with Wedbush PacGrow as the lead manager. The proceeds will support the development of innovative treatments for severe neuromuscular and cardiac disorders.
Edgewise Therapeutics (NASDAQ: EWTX) intends to offer and sell $100 million of its common stock in an underwritten public offering. An additional 30-day option for underwriters to purchase up to $15 million of common stock is also included. The offering is subject to market conditions and no assurance can be given regarding its completion or terms. J.P. Morgan and SVB Securities are acting as joint book-running managers. Edgewise focuses on innovative treatments for rare neuromuscular and cardiac disorders, indicating potential growth opportunities with the capital raised.
Edgewise Therapeutics (NASDAQ: EWTX) announced positive interim results from its ARCH study, focusing on the investigational drug EDG-5506 for Becker muscular dystrophy (BMD). After four months, participants exhibited an average 1.17-point increase in the North Star Ambulatory Assessment (NSAA) and significant reductions in muscle damage biomarkers: serum creatine kinase levels decreased by 29% and fast skeletal muscle troponin I by 74%. EDG-5506 was well-tolerated, with no serious adverse events. A webcast discussing the findings is scheduled for September 12 at 8:30 a.m. ET.
Edgewise Therapeutics (NASDAQ: EWTX) announced FDA authorization for the LYNX Phase 2 clinical trial of EDG-5506 in children with Duchenne Muscular Dystrophy (DMD). The trial aims to enroll approximately 27 participants, aged 4 to 9, across the U.S. to assess safety and efficacy over 12 weeks. EDG-5506, previously successful in BMD trials, is designed to mitigate muscle damage. Positive feedback from patient advocacy groups underscores the significance of expanding treatment options for DMD patients, a condition affecting 12,000-15,000 in the U.S.
Edgewise Therapeutics announced positive interim results for its EDG-5506 treatment in Becker muscular dystrophy (BMD) from the ARCH study. The ongoing trial indicates a significant reduction in muscle damage biomarkers, with creatine kinase and troponin I decreasing by 30% and 68%, respectively, after two months. The company has initiated Phase 2 trials for both BMD and plans for Duchenne muscular dystrophy (DMD) later in 2022. Financially, as of June 30, 2022, Edgewise reported
Edgewise Therapeutics (NASDAQ: EWTX) has announced that its senior management will participate in the virtual 2022 Wedbush PacGrow Healthcare Conference on August 9-10. The company is focused on developing therapies for rare muscle disorders. A live panel discussion titled “Muscle Beach” is scheduled for August 9 at 2:20 pm ET and will be available for replay. Edgewise employs a unique drug discovery platform aimed at treating severe neuromuscular and cardiac disorders.
FAQ
What is the current stock price of Edgewise Therapeutics (EWTX)?
What is the market cap of Edgewise Therapeutics (EWTX)?
What is Edgewise Therapeutics, Inc.?
Where is Edgewise Therapeutics located?
What is the core focus of Edgewise Therapeutics?
What are Edgewise Therapeutics' key projects?
Who financed Edgewise Therapeutics' Series A round?
Is Edgewise Therapeutics a public company?
What recent achievements has Edgewise Therapeutics made?
What kind of diseases is Edgewise Therapeutics targeting?
What type of therapies is Edgewise Therapeutics developing?